Sign in
Not yet taking people in FrancePhase 1

Study of how the body absorbs ziftomenib in relapsed or hard-to-treat AML or MDS

Tests how the body absorbs ziftomenib in adults with relapsed or unresponsive leukemia.

Key facts

Who runs it
Kura Oncology, Inc.
Where
Lille, Pessac, Pierre-Bénite, and Villejuif, FranceSee the 4 sitesAlso in 2 other countries, 7 sites
Registry title
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Status
Not yet recruiting
Phase
Phase 1
People taking part
126 people, planned
Started
30 Oct 2026
Expected to end
28 Feb 2029
Type of study
Interventional, 3 groups
Treatments tested
  • Ziftomenib
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) came back or did not respond to treatment, and who have certain gene changes.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
AML with an NPM1 mutation, or AML or MDS with a mutation linked to MEIS1 overexpression. The disease came back or did not respond to treatment. Standard-of-care treatment or stem cell transplant is not an option.
Earlier treatment
Standard-of-care treatment or hematopoietic stem cell transplantation (HSCT) is not an option for the person. Hydroxyurea or cytarabine may be used before the start to keep the white blood cell count down.
Biomarker or test result
NPM1 mutation in AML, or a mutation associated with MEIS1 overexpression in AML or MDS.

Main reasons for not taking part

  • Active leukemia in the brain or spinal cord area (central nervous system)
  • Serious graft-versus-host disease
  • Active, uncontrolled infection, including active HIV, hepatitis B or hepatitis C
  • Significant heart disease, or stroke or heart attack in the past 6 months
  • QTcF longer than 480 ms on the heart tracing (ECG)

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age ≥18 years
  • Relapsed/refractory NPM1-mutated AML, or relapsed/refractory AML or MDS with a mutation associated with MEIS1 overexpression; disease confirmed in blood and/or bone marrow, as applicable, and not a candidate for currently approved standard-of-care regimens or hematopoietic stem cell transplantation (HSCT)
  • Female participants must not be pregnant or breastfeeding
  • Male participants with partners of childbearing potential must agree to abstinence or highly effective contraception and refrain from sperm donation during treatment and for at least 90 days after the last dose
  • Signed informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and life expectancy ≥2 months
  • Adequate organ function: estimated glomerular filtration rate ≥30 mL/min/1.73 m²; bilirubin ≤1.5 × the upper limit of normal (ULN), unless attributable to Gilbert's syndrome or leukemic disease; and AST and ALT ≤3 × ULN
  • Peripheral white blood cell count ≤25,000/µL before Day 1 of Part 1; hydroxyurea or cytarabine may be used to control the count

Who cannot take part

  • Clinically active central nervous system (CNS) leukemia; participants with controlled CNS leukemia receiving intrathecal therapy at study entry may be eligible
  • Grade ≥2 acute graft-versus-host disease (GVHD), moderate/severe limited chronic GVHD, or extensive chronic GVHD
  • Active HIV, hepatitis C, or hepatitis B infection, as defined in the protocol; participants with controlled disease are not excluded
  • Active, uncontrolled systemic fungal, bacterial, viral, or other infection
  • Significant cardiovascular disease, including unstable angina, uncontrolled hypertension or arrhythmia, qualifying heart failure, ischemic or severe valvular heart disease, or stroke, transient ischemic attack, or myocardial infarction within the preceding 6 months
  • Mean QT interval corrected using Fridericia's formula (QTcF) >480 ms on triplicate electrocardiograms obtained within 5 minutes of each other; The full inclusion and exclusion criteria, including applicable definitions are presented in the study protocol

Where in France

Also in 2 other countries, 7 sites

  • Centre Hospitalier Universitaire de LilleLille, FranceNot yet recruiting
  • Centre Hospitalier Universitaire de BordeauxPessac, FranceNot yet recruiting
  • Hospices Civils de LyonPierre-Bénite, FranceNot yet recruiting
  • Institut Gustave RoussyVillejuif, FranceNot yet recruiting

About the trial

What the trial wants to find out

This study will evaluate the pharmacokinetics (PK) of ziftomenib drug products to inform relative bioavailability (rBA) and bioequivalence (BE) assessments.

The 3 groups in the trial

  • Cohort ATreatment being tested

    Sequential administration of oral formulations (Part 1) followed by optional treatment continuation (Part 2)

    Treatment: Ziftomenib

  • Cohort BTreatment being tested

    Sequential administration of oral formulations (Part 1) followed by optional treatment continuation (Part 2)

    Treatment: Ziftomenib

  • Cohort CTreatment being tested

    Sequential administration of oral formulations (Part 1) followed by optional treatment continuation (Part 2)

    Treatment: Ziftomenib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Relative Bioavailability and Bioequivalence Study of Ziftomenib Drug Products in Participants With Relapsed/Refractory AML With NPM1 Mutation, or With Relapsed/Refractory AML or MDS With Mutations Associated With MEIS1 Overexpression
Plain-language title
Study of how the body absorbs ziftomenib in relapsed or hard-to-treat AML or MDSGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 11 November 2026.
Record updated
10 November 2026